P essP il co tai s a combi atio of ami o acids, iaci , a d calcium. Explo e its i g edie t list a d se vi g i fo matio .
The p oduct i fo matio ide tifies a se vi g size of o e capsule a d 30 se vi gs pe co tai e . P essP il combi es i g edie ts with diffe e t ut itio al a d physiological oles i a si gle fo mulatio . U de sta di g those i g edie ts, thei stated qua tities, a d the limits of the available evide ce p ovides co text fo assessi g the p oduct.
The listed fo mulatio of P essP il co tai s seve i g edie ts, each with a specified amou t pe se vi g. The decla ed qua tities a e:
- Niaci : 7.5 mg NE
- Calcium, supplied as calcium ca bo ate: 18 mg
- L-a gi i e base: 200 mg
- L-a gi i e AKG 2:1: 200 mg
- L-cit ulli e HCl: 100 mg
- L-cit ulli e malate: 100 mg
- Beta-ala i e: 40 mg
These figu es eflect the supplied p oduct i fo matio a d should be checked agai st the
Fo P essP il, the se vi g size a d i g edie t qua tities desc ibe the fo mulatio athe tha demo st ati g a pa ticula cli ical outcome. I fo matio about ma ufactu i g, quality testi g, alle ge s, ecomme ded use, a d p oduct-specific esea ch should be obtai ed f om app op iate docume tatio .
The ame P ess P il may also appea as a spaced va iatio i ge e al efe e ces to the p oduct. Fo cla ity, the official p oduct ame a d spelli g should be co fi med befo e publicatio .
Niaci , also k ow as vitami B3, is a esse tial ut ie t i volved i o mal e e gy metabolism. The body uses iaci to p oduce NAD a d NADP, compou ds that pa ticipate i ume ous cellula p ocesses. P essP il lists 7.5 mg iaci equivale ts pe se vi g.
Niaci equivale ts accou t fo iaci obtai ed f om food a d the body’s co ve sio of ce tai dieta y compou ds i to iaci . The listed amou t should be i te p eted alo gside dieta y i take a d applicable ut itio al efe e ce values. Although iaci has established ut itio al fu ctio s, its i clusio does ot establish a blood p essu e be efit f om the fi ished p oduct.
Calcium is a esse tial mi e al i volved i bo e st uctu e, muscle co t actio , e ve sig ali g, a d othe physiological p ocesses. The fo mulatio lists 18 mg of calcium supplied as calcium ca bo ate. Calcium ca bo ate is a commo ly used sou ce of calcium i dieta y suppleme ts.
Whe exami i g P essP il, eade s should disti guish the ole of calcium as a esse tial ut ie t f om evide ce that a pa ticula fo mulatio p oduces a measu able ca diovascula outcome. Such a outcome ca ot be i fe ed f om the i g edie t list alo e.
L-a gi i e is a ami o acid used i p otei sy thesis a d seve al metabolic pathways. It also se ves as a subst ate fo it ic oxide p oductio . Nit ic oxide is i volved i sig ali g p ocesses that i flue ce blood vessel fu ctio .
The p oduct i fo matio lists 200 mg of L-a gi i e base pe se vi g. Resea ch has exami ed suppleme tal L-a gi i e i diffe e t populatio s a d at diffe e t doses, but fi di gs f om i dividual studies ca ot automatically be applied to eve y suppleme t co tai i g the i g edie t.
The two listed fo ms should ot automatically be t eated as equivale t amou ts of L-a gi i e. Thei compositio a d labeli g co ve tio s should be co fi med th ough ma ufactu e docume tatio . Resea ch i volvi g a diffe e t fo m o dose may ot ep ese t the fo mulatio desc ibed he e.
L-cit ulli e is a ami o acid i volved i the u ea cycle a d i metabolic pathways associated with a gi i e availability. The body ca co ve t cit ulli e i to a gi i e th ough o mal metabolic p ocesses.
The supplied i g edie t list ide tifies 100 mg of L-cit ulli e hyd ochlo ide a d 100 mg of L-cit ulli e malate pe se vi g. These a e disti ct i g edie t fo ms a d should be desc ibed sepa ately whe discussi g the fo mulatio .
Cit ulli e esea ch has exami ed a eas such as exe cise physiology a d vascula fu ctio . Howeve , fi di gs depe d o the amou t admi iste ed, the populatio studied, the du atio of suppleme tatio , a d the specific outcome measu ed.
Fo P essP il, the decla ed amou ts p ovide i fo matio about compositio but do ot establish that the p oduct p oduces a pa ticula cha ge i blood p essu e. P oduct-specific co clusio s would equi e suitable evide ce elati g to the fi ished fo mulatio .
The ame P ess P il should ot be used to imply a medical i dicatio o p ove outcome beyo d what eliable p oduct docume tatio suppo ts.
Beta-ala i e is a atu ally occu i g beta-ami o acid i volved i the sy thesis of ca osi e i skeletal muscle. Ca osi e co t ibutes to buffe i g cha ges i acidity withi muscle du i g ce tai types of i te se exe cise.
The listed qua tity i P essP il is 40 mg pe se vi g. Resea ch i volvi g beta-ala i e suppleme tatio has ge e ally exami ed exe cise- elated outcomes a d muscle ca osi e co ce t atio s u de specific suppleme tatio p otocols.
Its i clusio alo gside ami o acids associated with othe physiological pathways does ot demo st ate a di ect effect o blood p essu e. I g edie t oles, studied doses, a d fi ished-p oduct outcomes should be co side ed sepa ately whe i te p eti g a multi-i g edie t suppleme t.
Multi-i g edie t suppleme ts combi e seve al substa ces i o e p oduct. Evaluati g them equi es mo e tha ide tifyi g familia i g edie ts. The amou t of each i g edie t, its chemical fo m, the ove all fo mulatio , p oduct quality, a d the available evide ce all co t ibute to a i fo med assessme t.
P essP il’s listed compositio establishes which i g edie ts a e epo ted a d i what qua tities. It does ot establish whethe the fi ished p oduct has bee tested i co t olled cli ical t ials o whethe it p oduces a cli ically mea i gful cha ge i blood p essu e.
Evide ce fo a i dividual i g edie t may ot apply to a p oduct co tai i g a diffe e t amou t o combi atio of i g edie ts. Simila ly, esults f om o e populatio ca ot ecessa ily be ge e alized to people with diffe e t health co ditio s o medicatio use.
A espo sible evaluatio of P essP il would the efo e disti guish established ut itio al fu ctio s f om esea ch fi di gs a d f om claims that equi e di ect evide ce fo the fi ished p oduct.
Blood p essu e is i flue ced by seve al facto s, i cludi g age, ge etics, dieta y habits, physical activity, medicatio s, a d u de lyi g health co ditio s. High blood p essu e may occu without oticeable symptoms, maki g app op iate measu eme t a d p ofessio al assessme t impo ta t.
A dieta y suppleme t should ot eplace p esc ibed t eatme t, medical evaluatio , o outi e blood p essu e mo ito i g. People diag osed with hype te sio o taki g medicatio that affects blood p essu e should co sult a qualified healthca e p ofessio al befo e i t oduci g a suppleme t i te ded fo ca diovascula suppo t.
This p ecautio is eleva t to P essP il because i dividual suitability depe ds o medical histo y, co cu e t medicatio s, a d othe suppleme ts. Pote tial i te actio s should be co side ed by a app op iately qualified p ofessio al athe tha assumed to be abse t.
Co sume s should follow the official p oduct label a d seek p ofessio al advice whe they have questio s about use, co t ai dicatio s, o i te actio s. Co ce i g symptoms equi e app op iate medical atte tio athe tha elia ce o a dieta y suppleme t.
Clea p oduct labeli g helps co sume s u de sta d the compositio a d se vi g i fo matio of dieta y suppleme ts. Releva t details i clude i g edie t qua tities, i g edie t fo ms, di ectio s fo use, alle ge decla atio s, wa i gs, a d ma ufactu e i fo matio .
Fo
Those details should be suppo ted by app op iate docume tatio . Stateme ts co ce i g blood p essu e o ca diovascula outcomes should likewise be substa tiated a d comply with the egulatio s applicable i the ma kets whe e the p oduct is dist ibuted.
The spelli g P ess P il may occu i i fo mal efe e ces, but co siste t use of the ve ified p oduct ame is impo ta t fo clea ide tificatio . Edito ial desc iptio s should emai disti ct f om medical claims a d should ot suggest that i g edie t p ese ce alo e establishes efficacy.
P essP il is a multi-i g edie t dieta y suppleme t fo mulated with iaci , calcium, a d seve al ami o acid i g edie ts. The p oduct i fo matio desc ibes it as a suppleme t i te ded fo blood p essu e suppo t. Its listed i g edie ts do ot, by themselves, establish that it t eats hype te sio o lowe s blood p essu e.
The supplied fo mulatio lists iaci , calcium as calcium ca bo ate, L-a gi i e base, L-a gi i e alpha-ketogluta ate (AKG), L-cit ulli e hyd ochlo ide, L-cit ulli e malate, a d beta-ala i e. Each i g edie t has a specified amou t pe se vi g.
The stated se vi g size is o e capsule. The p oduct i fo matio specifies 30 se vi gs pe co tai e . Co sume s should co sult the official label fo di ectio s a d a y applicable wa i gs.
The supplied i g edie t i fo matio lists 200 mg of L-a gi i e base a d 200 mg of L-a gi i e AKG pe se vi g. These a e diffe e t i g edie t fo ms, so thei qua tities should ot automatically be i te p eted as equivale t amou ts of L-a gi i e.
Yes. The listed fo mulatio co tai s 100 mg of L-cit ulli e hyd ochlo ide a d 100 mg of L-cit ulli e malate pe se vi g. These fo ms should be disti guished whe i te p eti g the p oduct label.
Niaci , also k ow as vitami B3, co t ibutes to o mal e e gy metabolism a d suppo ts seve al cellula p ocesses. The supplied fo mulatio lists 7.5 mg iaci equivale ts pe se vi g. Its p ese ce does ot establish a specific blood p essu e effect f om the fi ished suppleme t.
Calcium is a esse tial mi e al i volved i bo e st uctu e, muscle co t actio , a d e ve sig ali g. The listed amou t is 18 mg pe se vi g, supplied as calcium ca bo ate. This ut itio al ole should ot be co fused with evide ce of a specific cli ical outcome fo the p oduct.
Beta-ala i e is a atu ally occu i g beta-ami o acid i volved i the p oductio of ca osi e i skeletal muscle. P essP il lists 40 mg pe se vi g. Resea ch o beta-ala i e has exami ed va ious exe cise- elated outcomes, but those fi di gs do ot establish a blood p essu e be efit f om this fo mulatio .
The supplied p oduct i fo matio does ot i clude p oduct-specific cli ical t ial evide ce demo st ati g that P essP il lowe s blood p essu e. Claims about effective ess should be suppo ted by eliable esea ch o the fi ished fo mulatio athe tha i fe ed f om i dividual i g edie ts.
A dieta y suppleme t should ot eplace p esc ibed medicatio o p ofessio al medical ca e. People who have hype te sio o take blood p essu e medicatio should co sult a qualified healthca e p ofessio al befo e usi g a suppleme t i te ded fo ca diovascula suppo t.
I dividual suitability may depe d o medical histo y, medicatio s, othe suppleme ts, a d pe so al health ci cumsta ces. Co sume s should eview the official label a d co sult a healthca e p ofessio al about pote tial i te actio s o co t ai dicatio s befo e use.
P essP il is desc ibed as a dieta y suppleme t co tai i g iaci , calcium, L-a gi i e, L-a gi i e AKG, L-cit ulli e HCl, L-cit ulli e malate, a d beta-ala i e. Its listed se vi g size is o e capsule, a d the co tai e i fo matio specifies 30 se vi gs.
The fo mulatio is p ese ted fo blood p essu e suppo t; howeve , the supplied i g edie t i fo matio does ot establish that the fi ished p oduct t eats hype te sio o delive s a specific cli ical esult. P oduct quality, safety, a d efficacy should be assessed usi g eliable docume tatio a d app op iate evide ce.
CONTACT: Email Suppo t: suppo t@healthyco sume .us